Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Letter Commentary & Co-Mentions | Period / Date | Action |
|---|---|---|---|
“Shares of Prime Medicine appreciated during the quarter, lifted late in June when the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to PM359, its Prime Edited stem-cell therapy for chronic granulomatous disease, based on Phase 1/2 data published in the New England Journal of Medicine. Days earlier, New...” | Q2 2026 Jun 30, 2026 | Preview | |
“Prime Medicine is a next-generation gene therapy company we have followed for a while, and believe the time is right to make an investment given our increasing confidence we have in their technology and the enormous upside potential should it prove viable. Prime's elegant and...” | Q4 2025 Dec 31, 2025 | Preview |
Read unredacted commentary excerpts, portfolio weight disclosures, and high-conviction theses from hedge fund managers discussing $PRME.
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
